This study examines the psychological and social factors influencing body donation decisions, highlighting family experiences ...

Adjunctive narrowband ultraviolet B (NB-UVB) phototherapy may help restore clinical response in patients with chronic plaque psoriasis who develop secondary failure to adalimumab, according to a small ...

An investigational immunomodulator gel significantly improved malodor and measures related to pain and quality of life for ...

New immune profiling data confirms disease-modifying mechanism, reinforces earlier signals of fibrosis resolution, lung repair, and improved lung ...

Lexaria Bioscience (LEXX) provides the following additional secondary and exploratory endpoint final results update on its Phase 1b, 12-week chronic study GLP-1-H24-4, recently completed in Australia, ...

KYZATREX ® is a controlled substance (CIII) because it contains testosterone. It is not known if KYZATREX ® is safe or effective in males younger than 18 years old. Improper use may affect bone growth ...

KELOWNA, BC / / December 30, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a ...

A warming planet has opened up new shipping routes and turned Greenland into a geostrategic asset for the Trump ...

Biomed Industries to Advance NA-931 Into Two Global Phase 3 Trials as Monotherapy and in Combination With Semaglutide and Tirzepatide for Obesity Advancing NA-931 into two Phase 3 programs as ...

HER2CLIMB-05 trial evaluated Tukysa in combination with Herceptin and Perjeta for HER2-positive metastatic breast cancer, ...

The FDA has granted Breakthrough Therapy designation to alixorexton for the treatment of narcolepsy type 1 (NT1).

KELOWNA, BC / ACCESS Newswire / December 30, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the follo ...